Cytokinetics, Incorporated
CYTK
$77.22
$2.413.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.01% | 817.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.01% | 817.10% | |||
| Cost of Revenue | -8.35% | 5.20% | |||
| Gross Profit | 11.90% | 10.95% | |||
| SG&A Expenses | 14.36% | 32.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.49% | 16.26% | |||
| Operating Income | -2.94% | -6.96% | |||
| Income Before Tax | -12.57% | 40.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.57% | 40.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.57% | 40.22% | |||
| EBIT | -2.94% | -6.96% | |||
| EBITDA | -2.70% | -6.97% | |||
| EPS Basic | -9.67% | 40.28% | |||
| Normalized Basic EPS | -9.67% | 1.12% | |||
| EPS Diluted | -9.67% | 40.28% | |||
| Normalized Diluted EPS | -9.67% | 1.12% | |||
| Average Basic Shares Outstanding | 2.64% | 0.10% | |||
| Average Diluted Shares Outstanding | 2.64% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||